528. HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES
Session: Poster Abstract Session: Hepatitis B and C in Varied Settings
Thursday, October 5, 2017
Room: Poster Hall CD
Posters
  • Poster# 528_IDSA2017_#63077_trt initiation in CKD.pdf (511.2 kB)
  • Background: Newer directing antiviral agents against HCV (DAAs) are safe and efficacious in persons with chronic kidney disease (CKD). Whether availability of these newer DAAs has resulted in more persons with CKD initiating HCV treatment remains unknown.

    Methods: We identified HCV+ persons in ERCHIVES. We excluded HIV+ and HBsAg+ and those with missing HCV RNA and eGFR data. We determined the CKD stage according to National Kidney Foundation criteria. We determined the number of persons initiated on any of the approved DAA-regimen (defined as >14 days of DAA prescription). Logistic regression analyses was used to determine factors associated with treatment initiation.

    Results: Among 76,513 evaluable persons, 21.1% initiated DAA treatment. Initiation rates differed significantly by CKD stage: 21.1% (15,136/68,469) for eGFR>90mL/min/1.73m2 and CKD stage-2; 14.0% 9853/6,086) for CKD stage 3; and 7.6% (148/1,958) for CKD stage-4/5. Those with CKD stage-3 were 35% less likely and those with CKD stage-4/5 were 65% less likely to initiate treatment with a DAA compared with those with baseline eGFR>90mL/min/1.73m2. Those with Body Mass Index (BMI)>30 were more likely to initiate treatment (OR 1.24, 95% CI 1.19,1.29). Treatment initiation was less likely in HCV genotype 2 or 3 and those with diabetes (OR 0.82, 95% CI 0.78,0.86), cardiovascular disease (OR 0.73, 95% CI 0.68,0.78), alcohol abuse or dependence (OR 0.75, 95% CI 0.72,0.78) or cirrhosis (OR 0.85, 95% CI 0.80,0.89) at baseline.

    Conclusion: Persons with more advanced CKD are less likely to receive treatment for HCV. Strategies are needed to improve treatment rates in the HCV/CKD population.

    Adeel Butt, MD, MS1, Yanjie Ren, MS2, Amy Puenpatom, PhD3, Jean Marie Arduino, ScD, MS3, Ritesh Kumar, PhD3 and Abdul-Badi Abou-Samra, MD, PhD4, (1)Weill Cornell Medical College, New York, NY, (2)VA Pittsburgh Healthcare System, Pittsburgh, PA, (3)Merck & Co., Inc., Kenilworth, NJ, (4)Hamad Medical Corporation, Doha, Qatar

    Disclosures:

    A. Butt, Merck: Investigator , Grant recipient

    Y. Ren, None

    A. Puenpatom, Merck: Employee , Salary

    J. M. Arduino, Merck: Employee , Salary

    R. Kumar, Merck: Employee , Salary

    A. B. Abou-Samra, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.